1-7 of 7
Axel Hauschild
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)

Aljosja Rogiers, Carlo Tondini, Joe M. Grimes, Megan H. Trager, Sharon Nahm, Leyre Zubiri, Neha Papneja, Arielle Elkrief, Jessica Borgers, April Rose, Johanna Mangana, Michael Erdmann, Ines Pires da Silva, Christian Posch, Axel Hauschild, Lisa Zimmer, Paola Queirolo, Caroline Robert, Karijn Suijkerbuijk, Paolo A. Ascierto, Paul Lorigan, Richard Carvajal, Osama E Rahma, Mario Mandala, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S02-01.
https://doi.org/10.1158/1557-3265.COVID-19-S02-01
Published: 15 September 2020
View article titled, Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI)
Journal Articles

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Michelle Casey, Georgina V. Long, Dirk Schadendorf, Keith Flaherty, Richard Kefford, Axel Hauschild, Patrick Hwu, Patricia Haney, Anne O'Hagan, Jennifer Carver, Vicki Goodman, Jeffrey Legos, Anne-Marie Martin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (3): 567–574.
https://doi.org/10.1158/1078-0432.CCR-15-0321
Published: 31 January 2016
View article titled, Correlation of <em>BRAF</em> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Open the PDF for Correlation of <em>BRAF</em> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Selma Ugurel, Thomas Mentzel, Jochen Utikal, Peter Helmbold, Peter Mohr, Claudia Pföhler, Meinhard Schiller, Axel Hauschild, Rüdiger Hein, Eckhardt Kämpgen, Ivonne Kellner, Martin Leverkus, Jürgen C. Becker, Philip Ströbel, Dirk Schadendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 499–510.
https://doi.org/10.1158/1078-0432.CCR-13-1411
Published: 16 January 2014
View article titled, Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up
Open the PDF for Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

John M. Kirkwood, Paul Lorigan, Peter Hersey, Axel Hauschild, Caroline Robert, David McDermott, Margaret A. Marshall, Jesus Gomez-Navarro, Jane Q. Liang, Cecile A. Bulanhagui
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 1042–1048.
https://doi.org/10.1158/1078-0432.CCR-09-2033
Published: 01 February 2010
View article titled, Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
Open the PDF for Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma in another window
Journal Articles

A Multimarker Prognostic Assay for Primary Cutaneous Melanoma

Mohammed Kashani-Sabet, Suraj Venna, Mehdi Nosrati, Javier Rangel, Antje Sucker, Friederike Egberts, Frederick L. Baehner, Jeff Simko, Stanley P.L. Leong, Chris Haqq, Axel Hauschild, Dirk Schadendorf, James R. Miller, III, Richard W. Sagebiel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 6987–6992.
https://doi.org/10.1158/1078-0432.CCR-09-1777
Published: 11 November 2009
View article titled, A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Open the PDF for A Multimarker Prognostic Assay for Primary Cutaneous Melanoma in another window
Journal Articles

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Reinhard Dummer, Axel Hauschild, Juergen C. Becker, Jean-Jacques Grob, Dirk Schadendorf, Veronica Tebbs, Jeannine Skalsky, Katharina C. Kaehler, Stephanie Moosbauer, Ruth Clark, Tze-Chiang Meng, Mirjana Urosevic
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 856–864.
https://doi.org/10.1158/1078-0432.CCR-07-1938
Published: 01 February 2008
View article titled, An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma
Open the PDF for An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group

Selma Ugurel, Dirk Schadendorf, Claudia Pföhler, Karsten Neuber, Adina Thoelke, Jens Ulrich, Axel Hauschild, Konstanze Spieth, Martin Kaatz, Werner Rittgen, Stefan Delorme, Wolfgang Tilgen, Uwe Reinhold
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5454–5463.
https://doi.org/10.1158/1078-0432.CCR-05-2763
Published: 25 September 2006
View article titled, <em>In vitro</em> Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group
Open the PDF for <em>In vitro</em> Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group in another window
Includes: Supplementary data